YMR230W-A Antibody

What is the optimal application of YMR230W-A Antibody in yeast protein detection studies?

YMR230W-A Antibody is most effectively utilized in Western blotting, immunoprecipitation, and immunofluorescence microscopy applications for detecting the encoded protein in Saccharomyces cerevisiae. For Western blotting, researchers should optimize protein extraction by using either glass bead disruption or enzymatic lysis methods specifically designed for yeast cell walls. The recommended dilution range starts at 1:500-1:2000, though optimization for specific experimental conditions is essential. For immunofluorescence, fixation with 3.7% formaldehyde followed by spheroplasting with zymolyase typically yields optimal results when visualizing yeast cellular components. In all applications, including appropriate positive and negative controls is critical for result validation and experimental reproducibility .

How does sample preparation affect YMR230W-A Antibody binding efficiency in yeast extracts?

Sample preparation significantly impacts antibody binding efficiency when working with yeast extracts. The thick cell wall of Saccharomyces cerevisiae requires specialized lysis methods to ensure complete protein extraction while maintaining protein integrity. Mechanical disruption (using glass beads) coupled with detergent-based buffers containing protease inhibitors is recommended for total protein extraction. For membrane-associated proteins, specialized detergents like digitonin or DDM may be necessary. The lysis buffer pH should be maintained between 7.2-7.4 to preserve antibody binding sites. Additionally, researchers should avoid excessive heat during extraction, as this may denature epitopes recognized by the YMR230W-A Antibody. For optimal results, fresh samples yield better signal-to-noise ratios compared to frozen extracts, particularly when studying post-translational modifications or protein complexes.

What cross-reactivity considerations should researchers address when using YMR230W-A Antibody?

When working with YMR230W-A Antibody, researchers must consider potential cross-reactivity with similar epitopes in related yeast proteins or in proteins from other organisms if conducting comparative studies. Initial validation through Western blotting using wild-type and knockout strains is recommended to verify specificity. If cross-reactivity occurs, increasing the stringency of washing steps (using buffers containing higher salt concentrations or mild detergents like 0.1% Tween-20) can reduce non-specific binding. Pre-absorption with yeast lysates lacking the target protein can also improve specificity. For experiments requiring absolute specificity, competitive binding assays using purified recombinant YMR230W-A protein can confirm antibody selectivity. Researchers should also note that cross-reactivity profiles may differ between applications (Western blotting versus immunoprecipitation or immunofluorescence), necessitating application-specific validation .

How should researchers design experiments to investigate YMR230W-A protein expression under different stress conditions?

When investigating YMR230W-A protein expression under varying stress conditions, researchers should implement a systematic experimental design incorporating time-course analyses and dose-response relationships. Begin by establishing baseline expression levels in standard growth conditions using quantitative Western blotting with the YMR230W-A Antibody at 1:1000 dilution. For stress induction, expose yeast cultures to relevant stressors (oxidative stress using hydrogen peroxide, heat shock, nutrient limitation, or osmotic stress) at multiple intensities and duration periods. Include appropriate housekeeping protein controls (such as actin or GAPDH) for normalization. Complementary approaches should include RT-qPCR to correlate protein expression with transcript levels. For each experimental condition, maintain biological triplicates and technical duplicates to ensure statistical validity. Time-course experiments are particularly valuable, revealing expression kinetics from early response (15-30 minutes) through long-term adaptation (4-24 hours). Integration of microscopy techniques using the same antibody can further elucidate subcellular localization changes in response to stress conditions.

What protocols ensure optimal immunoprecipitation results when using YMR230W-A Antibody for protein-protein interaction studies?

For protein-protein interaction studies using YMR230W-A Antibody in immunoprecipitation (IP) protocols, several methodological considerations are critical for success. Begin with optimized cell lysis using a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, and protease inhibitor cocktail, which preserves protein complexes while minimizing non-specific interactions. Pre-clear lysates with Protein A/G beads for 1 hour at 4°C to reduce background. Incubate pre-cleared lysates with 2-5 μg of YMR230W-A Antibody overnight at 4°C with gentle rotation, followed by addition of fresh Protein A/G beads for 2-4 hours. Include matched isotype control antibodies in parallel reactions to identify non-specific binding. For crosslinking applications, use DSP (dithiobis[succinimidyl propionate]) at 1-2 mM final concentration to stabilize transient interactions. After washing with increasingly stringent buffers (containing 150-300 mM NaCl), elute complexes using either low pH glycine buffer or by boiling in SDS-sample buffer. For detecting novel interactions, consider mild detergents like digitonin (0.5-1%) to preserve weaker protein-protein associations. Validation of interactions should combine IP-Western blotting with reverse co-IP experiments and proximity ligation assays when possible.

How can researchers effectively use YMR230W-A Antibody for chromatin immunoprecipitation (ChIP) experiments?

For chromatin immunoprecipitation (ChIP) experiments using YMR230W-A Antibody, researchers should implement specialized protocols optimized for yeast chromatin structure. Begin with formaldehyde crosslinking (1% for 15-20 minutes) of mid-log phase yeast cultures, followed by quenching with glycine. Cell lysis requires specialized approaches for yeast, including enzymatic digestion with zymolyase (100T at 1 mg/ml for 30 minutes at 30°C) prior to mechanical disruption. Chromatin sonication parameters must be carefully optimized (typically 10-15 cycles of 30 seconds on/30 seconds off at medium power) to yield fragments averaging 200-500 bp. For the immunoprecipitation step, use 3-5 μg of YMR230W-A Antibody per reaction with an overnight incubation at 4°C. Include input controls, IgG negative controls, and positive controls (antibodies against known DNA-binding proteins) in each experiment. After washing with increasingly stringent buffers, reverse crosslinks by heating at 65°C for 4-6 hours. DNA purification, quantification, and analysis by qPCR or sequencing complete the protocol. For targeted analyses, design qPCR primers spanning predicted binding regions and appropriate negative control regions. Calculate fold enrichment using the percent input method rather than relative enrichment to IgG for more accurate quantification.

What are the common causes of weak or absent signals when using YMR230W-A Antibody in Western blots, and how can these issues be resolved?

Several factors can contribute to weak or absent signals when using YMR230W-A Antibody in Western blotting of yeast proteins. The primary issues and their methodological solutions include:

• Inefficient protein extraction: Yeast cell walls require specialized lysis methods. Implement mechanical disruption with glass beads in combination with detergent-based lysis buffers containing 1% Triton X-100 or 0.1% SDS. For difficult samples, consider enzymatic pre-treatment with zymolyase (5-10 units/OD₆₀₀ of cells) to weaken cell walls before mechanical disruption.

• Protein degradation: Add a comprehensive protease inhibitor cocktail specifically formulated for yeast (including PMSF, leupeptin, pepstatin A, and aprotinin) to all buffers. Maintain samples at 4°C throughout processing and avoid repeated freeze-thaw cycles.

• Inefficient transfer: For yeast proteins, semi-dry transfer systems may be less effective than wet transfer methods. Use PVDF membranes rather than nitrocellulose for improved protein retention, and consider adding 0.1% SDS to the transfer buffer to improve elution of proteins from gels.

• Suboptimal antibody conditions: Titrate antibody concentrations (1:500, 1:1000, 1:2000) and incubation times (overnight at 4°C versus 2-4 hours at room temperature). Add 0.5% BSA to blocking solutions to reduce background while preserving specific signals.

• Low protein expression: Increase loading amounts (40-60 μg per lane) or consider concentration methods such as TCA precipitation. For low-abundance proteins, implement signal enhancement systems such as biotin-streptavidin amplification.

For persistent issues, validate antibody functionality using positive control samples containing recombinant YMR230W-A protein or lysates from strains overexpressing the target protein .

How should researchers approach contradictory data when comparing YMR230W-A protein abundance across different detection methods?

When faced with contradictory data regarding YMR230W-A protein abundance across different detection methods, researchers should implement a systematic troubleshooting and validation approach:

• Method-specific artifacts assessment: Each detection method (Western blot, ELISA, mass spectrometry, immunofluorescence) has inherent biases. Western blotting may be influenced by transfer efficiency and membrane binding, while mass spectrometry results depend on ionization efficiency and peptide recovery. Document methodological details for each technique, including antibody concentrations, detection systems, and quantification approaches.

• Sample preparation comparison: Variations in extraction buffers, detergents, and lysis methods can differentially affect protein recovery. Standardize preparation methods or directly compare extraction efficiencies using spike-in controls of known concentration.

• Antibody epitope accessibility analysis: Post-translational modifications or protein-protein interactions may mask epitopes in native conditions but not in denatured states. Perform epitope mapping experiments and consider using multiple antibodies targeting different regions of the YMR230W-A protein.

• Quantification method validation: Compare relative versus absolute quantification approaches. Implement standard curves using purified recombinant protein for absolute quantification, and ensure linearity of detection across the relevant concentration range.

• Biological variability assessment: Document growth conditions, strain background, and cell cycle stage, as these factors can significantly impact protein abundance. Synchronize cultures when appropriate and increase biological replicates to strengthen statistical analyses.

• Orthogonal validation: Implement genetic approaches such as epitope tagging (HA, FLAG, or GFP tags) to provide independent verification of protein abundance patterns. Correlate protein levels with transcript abundance using RT-qPCR while acknowledging that post-transcriptional regulation may cause discrepancies.

When reporting results, transparently document these methodological differences and provide a balanced interpretation that acknowledges the strengths and limitations of each approach.

What statistical approaches are most appropriate for analyzing quantitative data generated using YMR230W-A Antibody?

When analyzing quantitative data generated using YMR230W-A Antibody, researchers should employ robust statistical approaches tailored to the specific experimental design and data characteristics:

• Data preprocessing and normalization: For Western blot densitometry, normalize target protein signals to appropriate housekeeping proteins (actin, GAPDH, or tubulin) using ratio or ANCOVA approaches rather than simple subtraction methods. For immunofluorescence quantification, implement background subtraction using adjacent non-stained regions followed by cell-by-cell normalization to account for cell size variations.

• Distribution assessment: Before selecting statistical tests, verify data normality using Shapiro-Wilk or Kolmogorov-Smirnov tests. For non-normally distributed data, apply appropriate transformations (log, square root) or use non-parametric alternatives.

• Experimental design-appropriate analyses: For comparing multiple experimental conditions, implement one-way or two-way ANOVA with appropriate post-hoc tests (Tukey's HSD for balanced designs, Scheffé's method for unbalanced designs). For time-course experiments, apply repeated measures ANOVA or mixed-effects models to account for temporal correlation.

• Replication strategy implementation: Distinguish between technical replicates (repeated measurements of the same sample) and biological replicates (independent samples). Power analyses should guide replicate numbers, with a minimum of three biological replicates recommended. Technical variability can be incorporated using nested ANOVA designs.

• Multiple testing correction: When measuring YMR230W-A protein levels across multiple conditions or time points, implement Benjamini-Hochberg procedure for controlling false discovery rate rather than the more conservative Bonferroni correction.

• Effect size reporting: Supplement p-values with appropriate effect size measurements (Cohen's d for parametric tests, r for non-parametric tests) and confidence intervals to provide insight into biological significance beyond statistical significance.

For complex experimental designs involving multiple factors, consider consulting with a biostatistician to develop appropriate analytical approaches and ensure robust interpretation of YMR230W-A Antibody-generated data.

How can researchers effectively use YMR230W-A Antibody in combination with other molecular tools for comprehensive functional studies?

Advanced functional studies using YMR230W-A Antibody can be enhanced through strategic integration with complementary molecular approaches:

• CRISPR-Cas9 genetic modification: Combine YMR230W-A Antibody-based protein detection with precise genome editing to create point mutations, deletions, or insertions in the coding sequence or regulatory regions. This enables correlation between specific genetic alterations and resulting protein expression patterns. For yeast-specific applications, optimize CRISPR-Cas9 delivery using appropriate selection markers and homology-directed repair templates.

• Proximity-dependent labeling: Implement BioID or APEX2 fusion constructs with YMR230W-A to identify proximal proteins in living cells. Follow with immunoprecipitation using the YMR230W-A Antibody and mass spectrometry analysis to validate interaction partners. This approach is particularly valuable for identifying transient or weak interactions that may be lost in traditional co-immunoprecipitation experiments.

• Live-cell imaging integration: Combine fixed-cell immunofluorescence using YMR230W-A Antibody with live-cell imaging of fluorescently tagged versions of the protein. This dual approach allows correlation between dynamic behaviors observed in living cells and precise localization patterns detected through antibody staining at specific timepoints.

• Ribosome profiling correlation: Analyze translational regulation by comparing YMR230W-A protein levels (detected by the antibody) with ribosome-protected fragment abundance. This approach reveals post-transcriptional regulatory mechanisms affecting protein production efficiency.

• Single-cell analysis: Adapt immunofluorescence protocols using YMR230W-A Antibody for flow cytometry or mass cytometry (CyTOF) applications to quantify cell-to-cell variability in protein expression. Correlate these measurements with single-cell RNA-sequencing data to explore the relationship between transcriptional and translational heterogeneity.

• Systematic genetic interaction mapping: Combine YMR230W-A Antibody-based protein quantification with synthetic genetic array (SGA) analyses to correlate genetic interactions with changes in protein abundance, localization, or modification state across thousands of yeast mutant backgrounds.

These integrated approaches create a multi-dimensional understanding of YMR230W-A function beyond what can be achieved using the antibody alone .

What are the latest methodological advances in using YMR230W-A Antibody for studying protein dynamics and post-translational modifications?

Recent methodological advances have expanded the applications of YMR230W-A Antibody for investigating protein dynamics and post-translational modifications:

• Quantitative multiplexed immunoblotting: Implementing multiplexed detection systems such as LI-COR's fluorescence-based Western blotting allows simultaneous detection of YMR230W-A and its modified forms or interacting partners. This approach enables precise quantification across wide dynamic ranges without the limitations of chemiluminescence.

• Sequential immunoprecipitation workflows: Advanced protocols now combine traditional immunoprecipitation with YMR230W-A Antibody followed by secondary immunoprecipitation using modification-specific antibodies (phospho, ubiquitin, SUMO, or acetyl-lysine). This sequential approach enriches specific modified populations of the protein for downstream analysis.

• Pulse-chase immunoprecipitation: Coupling metabolic labeling (with 35S-methionine or SILAC approaches) with time-resolved immunoprecipitation using YMR230W-A Antibody allows determination of protein half-life and degradation kinetics under various experimental conditions.

• Proximity ligation assays (PLA): These assays combine YMR230W-A Antibody with antibodies against suspected interacting partners or specific modifications. The technique generates fluorescent signals only when proteins are within 40 nm of each other, providing spatial information about interactions and modifications in situ.

• ChIP-SICAP (Selective Isolation of Chromatin-Associated Proteins): This technique combines chromatin immunoprecipitation using YMR230W-A Antibody with biotin-tagging of DNA-associated proteins, allowing purification and mass spectrometric identification of the complete protein complex associated with chromatin-bound YMR230W-A.

• FRAP-IP correlation: Fluorescence Recovery After Photobleaching (FRAP) of fluorescently-tagged YMR230W-A protein can be combined with immunoprecipitation using the antibody from specific cellular fractions to correlate dynamic behavior with protein interaction landscapes.

• Cross-linking mass spectrometry (XL-MS): Implementing protein cross-linking prior to immunoprecipitation with YMR230W-A Antibody preserves transient interactions and allows mass spectrometric determination of interaction interfaces at amino acid resolution.

These methodological innovations significantly enhance the research value of YMR230W-A Antibody for investigating complex aspects of protein function beyond simple detection and quantification.

How can researchers design experiments to investigate the role of YMR230W-A in stress response pathways using the corresponding antibody?

Designing experiments to investigate YMR230W-A's role in stress response pathways requires a multi-faceted approach leveraging the specificity of the corresponding antibody:

• Stress-specific expression profiling: Implement a systematic analysis of YMR230W-A protein levels across diverse stress conditions (oxidative, osmotic, heat shock, nutrient limitation, DNA damage) using quantitative Western blotting with the antibody. Design time-course experiments (0, 15, 30, 60, 120 minutes, 4, 8, 24 hours) to distinguish between immediate and adaptive responses. Include appropriate controls such as known stress-responsive proteins (e.g., Hsp104 for heat shock, Tsa1 for oxidative stress).

• Subcellular relocalization analysis: Perform immunofluorescence microscopy using the YMR230W-A Antibody before and after stress induction to track potential relocalization events. Co-stain with organelle-specific markers (DAPI for nucleus, mitotracker for mitochondria) to precisely determine localization changes. Implement high-content imaging for quantitative assessment of distribution patterns across hundreds of cells.

• Protein modification profiling: Combine immunoprecipitation using YMR230W-A Antibody with mass spectrometry to identify stress-induced post-translational modifications. Focus on phosphorylation, ubiquitination, and SUMOylation, which are common regulatory modifications in stress responses. Validate findings using modification-specific antibodies in Western blotting.

• Protein interaction dynamics: Perform co-immunoprecipitation with YMR230W-A Antibody before and after stress induction to identify stress-specific interaction partners. Implement SILAC or TMT labeling for quantitative comparison of interaction profiles across conditions. Validate key interactions through reverse co-immunoprecipitation and proximity ligation assays.

• Functional ablation correlation: Compare stress responses between wild-type and YMR230W-A deletion/depletion strains by measuring survival rates, growth curves, and known stress markers. Use the antibody to confirm protein absence in knockout strains and depletion in conditional systems.

• Genetic pathway mapping: Combine YMR230W-A Antibody-based protein analysis with genetic approaches by examining protein levels and modifications in strains lacking known stress response regulators (e.g., Hog1, Msn2/4, Yap1). This approach places YMR230W-A within established stress response pathways.

• Chromatin association dynamics: Implement ChIP-seq using YMR230W-A Antibody before and after stress exposure to identify potential stress-dependent DNA binding sites if the protein has nuclear functions. Correlate binding patterns with transcriptional changes measured by RNA-seq.

This comprehensive experimental strategy provides mechanistic insights into YMR230W-A's role in stress response pathways while leveraging the specificity of the antibody for detection and functional characterization.

How should researchers integrate YMR230W-A expression data with transcriptomic and proteomic datasets?

Effective integration of YMR230W-A expression data with transcriptomic and proteomic datasets requires sophisticated analytical approaches:

• Multi-omics correlation analysis: Calculate Pearson or Spearman correlation coefficients between YMR230W-A protein levels (measured using the antibody) and corresponding mRNA levels across multiple experimental conditions. Deviations from correlation may indicate post-transcriptional regulation. Implement time-lag analyses to account for delays between transcription and translation, typically using 15-30 minute offsets in rapidly changing conditions.

• Protein complex co-expression networks: Construct protein co-expression networks from proteomic data, identifying modules containing YMR230W-A. Use the antibody to validate co-expression relationships for key network nodes through targeted Western blotting. Apply weighted gene correlation network analysis (WGCNA) to identify condition-specific modules.

• Pathway enrichment integration: Perform pathway enrichment analysis separately on transcriptomic and proteomic datasets, then identify overlapping and distinct enriched pathways. Position YMR230W-A within these pathways based on antibody-derived expression patterns and known interactions.

• Transcription factor binding correlation: Integrate ChIP-seq data for transcription factors with YMR230W-A expression patterns to identify potential regulatory relationships. Validate key relationships using promoter-reporter assays and antibody-based detection of expression changes following transcription factor perturbation.

• Post-translational modification landscape: Map YMR230W-A post-translational modifications identified through immunoprecipitation and mass spectrometry to modification databases (such as PhosphoGRID for yeast proteins). Correlate modification patterns with changing expression levels across conditions.

• Protein localization context: Integrate immunofluorescence data using the YMR230W-A Antibody with transcriptomic changes in subcellular compartment-specific genes to provide spatial context for expression changes.

• Cross-species conservation analysis: Compare YMR230W-A expression patterns with orthologs in other yeast species or model organisms, identifying conserved and divergent regulatory features. Use the antibody to confirm expression patterns in S. cerevisiae as a reference point.

• Visualization and data sharing: Implement interactive visualization tools (such as Cytoscape for network analysis or heatmaps for expression patterns) to effectively communicate integrated datasets. Deposit standardized data in repositories such as PRIDE for proteomics and GEO for transcriptomics to enable community reuse.

This integrated approach provides a comprehensive systems-level understanding of YMR230W-A function beyond isolated antibody-based detection.

What are the best practices for databasing and sharing YMR230W-A Antibody validation and experimental data within the research community?

Establishing best practices for databasing and sharing YMR230W-A Antibody validation and experimental data requires adherence to FAIR principles (Findable, Accessible, Interoperable, Reusable) while addressing field-specific considerations:

• Comprehensive validation reporting: Document detailed validation data including Western blot images showing full membranes with molecular weight markers, immunoprecipitation efficiency metrics, specificity controls using knockout strains, and cross-reactivity testing. These should be compiled into standardized formats following Antibody Validation Working Group guidelines.

• Structured metadata documentation: Create detailed metadata records including:

  • Antibody specifications: Host species, clonality, immunogen sequence, purification method

  • Validation methods: Tests performed with quantitative success criteria

  • Experimental conditions: Buffer compositions, incubation times/temperatures, dilutions

  • Batch/lot information: Production date, lot number, storage conditions

  • Equipment parameters: Imaging settings, exposure times, gain values

• Repository submission protocols: Submit validation data to specialized repositories including:

  • Antibodypedia for antibody-specific information

  • PRIDE for mass spectrometry-based validation

  • Image Data Resource (IDR) for microscopy validation
    Each submission should include both raw and processed data with appropriate quality control metrics.

• Standardized reporting formats: Implement community standards such as:

  • Minimum Information About a Protein Affinity Reagent (MIAPAR)

  • Protein Capture Reagents Program standards

  • Antibody Registry unique identifiers for consistent referencing

• Version control implementation: Establish version control protocols for tracking changes in antibody performance across production batches. Document any shifts in specificity, sensitivity, or optimal conditions.

• Interoperability considerations: Ensure data formats are machine-readable using:

  • Structured data formats (JSON, XML) for experimental parameters

  • Standard ontologies for experimental descriptions (PSI-MS for mass spectrometry, MIAPE for proteomics)

  • Consistent identifiers linked to UniProt (Q3E7B5) for YMR230W-A

• Open science practices: Promote transparency through:

  • Pre-registration of validation protocols

  • Open notebook documentation of optimization processes

  • Publication of negative results and failed validation attempts

  • Sharing of detailed protocols via protocols.io or similar platforms

• Community engagement mechanisms: Establish feedback channels for:

  • Reporting application-specific optimizations

  • Documenting batch-to-batch variability

  • Sharing troubleshooting solutions

  • Coordinating interlaboratory validation studies

These practices ensure that YMR230W-A Antibody data can be effectively utilized by the broader research community while maintaining high standards of reproducibility and transparency .

What ethical considerations should researchers address when developing and using antibodies against yeast proteins like YMR230W-A?

While yeast research doesn't raise the same ethical concerns as research involving animals or humans, researchers developing and using antibodies against yeast proteins like YMR230W-A should address several important ethical and methodological considerations:

• Animal welfare in antibody production: If YMR230W-A Antibody was developed using animal immunization (rabbits, mice, or other species), researchers should review and report adherence to the 3Rs principles (Replacement, Reduction, Refinement). When possible, recombinant antibody technologies that don't require animal immunization should be considered for future development. For polyclonal antibodies requiring animals, researchers should document adherence to institutional animal care guidelines and international standards.

• Research integrity practices: Implement robust validation protocols to prevent research waste and irreproducible results. This includes thorough specificity testing against knockout strains, off-target binding assessment, and batch-to-batch consistency evaluation. Transparency in reporting negative results or limitations of the antibody is essential for maintaining research integrity.

• Resource sharing obligations: Consider equitable access to research tools, especially for antibodies developed using public funding. Material transfer agreements should balance intellectual property protection with scientific advancement through reasonable sharing provisions. Where possible, publish complete immunogen sequences to allow reproduction by other laboratories.

• Environmental considerations: Document proper disposal methods for hazardous materials used in antibody production and application (including chemical fixatives, organic solvents, and heavy metals used in some detection systems). Implement waste reduction strategies in experimental design.

• Data stewardship responsibilities: Maintain comprehensive records of antibody validation data, experimental protocols, and raw results to facilitate reproducibility. Deposit data in appropriate repositories with sufficient metadata to enable reuse by other researchers.

• Credit attribution practices: Ensure proper acknowledgment of antibody developers, commercial suppliers, and funding sources that supported tool development. When using antibodies developed by others, cite original validation studies rather than only commercial sources.

• Disclosure of competing interests: Transparently report any financial interests, including antibody commercialization plans or relationships with companies producing research reagents, that might influence research design or reporting.

• Methodological alternatives consideration: Evaluate whether complementary approaches (such as epitope tagging) might provide more reliable results for specific applications, rather than defaulting to antibody-based methods where they may have limitations.